Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17411406 | 0.83 | TSHR (0.47) | TSHRMAOAMAOBSRD5A2HPGD | |
| SCHEMBL16795752 | 0.81 | TSHR (0.48) | TSHRMAOAMAOBSRD5A2HPGD | |
| SCHEMBL2016516 | 0.79 | TSHR (0.47) | TSHRMAOAMAOBSRD5A2HPGD | |
| SCHEMBL990763 | 0.79 | TSHR (0.47) | TSHRMAOAMAOBSRD5A2HPGD | |
| SCHEMBL3194118 | 0.78 | HPGD (0.47) | TSHRMAOAMAOBSRD5A2HPGD | |
| SCHEMBL20619804 | 0.76 | MAOA (0.44) | TSHRMAOAMAOBSRD5A2HPGD | |
| SCHEMBL13958953 | 0.76 | MAOA (0.55) | TSHRMAOAMAOBSRD5A2KDM4E | |
| SCHEMBL23792292 | 0.75 | HPGD (0.50) | TSHRMAOAMAOBHPGDKMO | |
| SCHEMBL2017777 | 0.73 | TSHR (0.49) | TSHRMAOAMAOBHPGDHTT | |
| SCHEMBL28601272 | 0.73 | TSHR (0.54) | TSHRSRD5A2HPGDPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3759098-A1 | PYRIDINE-SULFONAMIDE COMPOUNDS AND THEIR USE AGAINST PAIN AND RELATED CONDITIONS | Genentech, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| CN-112041313-A | Pyridine-sulfonamide compounds and their use against pain and related conditions | 基因泰克公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2019165290-A1 | PYRIDINE-SULFONAMIDE COMPOUNDS AND THEIR USE AGAINST PAIN AND RELATED CONDITIONS | GENENTECH, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | ASAH2, ACER2, PCSK9 | TSHR 2777/4885MAOA 2521/4885MAOB 1656/4885 |
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | TRPV1, HCN4, TRPA1 | TSHR 3613/4885MAOA 2896/4885MAOB 1125/4885 |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | TRPV1, HCN4, TRPA1 | TSHR 3613/4885MAOA 2896/4885MAOB 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.